JUNS logo

JUPITER NEUROSCIENCES INC

JUNSNASDAQ
🏆 #5261 by market capUS Equity
$2.53▼ $0.28 (−10.92%)
Live
🔔
Track JUNS
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 10.9%
7d▼ 19.7%
14d▼ 20.8%
30d▼ 44.9%
ytd▼ 96.9%
1y▼ 98.1%
🏦Market Cap
$143M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
54.4x
Expensive
Otter Score
44
Weak

Trading Snapshot

Day Range
$2.50 – $2.56
52-Week Range
$2.67 – $138.00
Volume
$1.69B
Avg Volume
$1.68B
Shares Outstanding
56.5M
Next Earnings
Dec 12, 2026

Fundamentals Snapshot

Annual Revenue
$64,700
Last Q Revenue
$18,001
P/E Ratio
—
P/S Ratio
54.4x
EPS (TTM)
$-18.57
Dividend Yield
—

Why Investors Own JUNS

  • ✓High-growth profile — revenue up -1.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 27% gross margin and 29% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

JUNS logo

JUPITER NEUROSCIENCES INC

JUNS
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$64,700▼ −1.6% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
27.0%▲ +2.4% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$11,905▼ −1.6% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$18,569▼ −1.6% YoY
StockOtter · stockotter.space

About JUPITER NEUROSCIENCES INC

Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
44/100

Analyst Price Target

ⓘ
Average Target
$3.26
▲ +28.9% Upside
High Target$3.95
Low Target$2.73
Based on 34 analysts

Latest News & Updates

🚀
Reuters·2h ago

JUPITER NEUROSCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift JUNS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

JUPITER NEUROSCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.